Treatment of Venous Thromboembolism

Heart Disease

Volumn 2, Issue 6, 2000, Pages 438-445

  Nazario, Roderick ^a   Dclorenzo, Lawrence J ^a   Maguire, George P ^a,c   Dobkin, Jay ^b   Reichel, Joseph ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Heparin; Inferior vena cava filter; Low molecular weight heparin; Pulmonary embolism; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

EMBOLECTOMY; HUMAN; PATHOPHYSIOLOGY; REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; EMBOLECTOMY; FIBRINOLYTIC AGENTS; HUMAN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0034329566     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hyers TM. State of the art: venous thromboembolism. Am J Respir Crit Care Med 1999;159:1-14.
2. Goldhaber SZ. Pulmonary embolism. N Engl Med 1998;339:93-104.
3. Moser KM, Fedullo PF, LitteJohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep vein thrombosis. JAMA 1994;27:8223-8225.
4. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978-981.
5. Heit JA, Solverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999;159:445-453.
6. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335:1816-1826.
7. Giuntini RC, Diricco G, Marini C, et al. Updates on pulmonary embolism: epidemiology. Chest 1995;107(Suppl):35-95.
8. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997;127:895-903.
9. Hull KD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. Arch Intern Med 1997;157:2317-2321.
10. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998;114(Suppl):561S-78S.
11. Ranschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "Standard Care" nomogram. Ann Intern Med 1993;119:874-881.
12. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152: 1589-1595.
13. Weitz, JI. Low molecular weight heparins. N Engl J Med 1997;337:688-698.
14. Agular D, Goldhaber SZ. Clinical uses of low molecular weight heparins. Chest 1999;115:1418-1423.
15. Buller HR, Gent M, Gallus AS, et al. Low molecular weight heparin in the treatment of patients with venous thrombosis. N Engl J Med 1997;337:657-662.
16. Simmoneau G, Sors H, Charbonnier B, et al. A comparison of low molecular weight heparin with unfractioned heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669.
17. Hull RD, Raskob GE, Brant RF, etal. Low molecular weight heparin vs. heparin in the treatment in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-236.
18. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular weight heparins with unfractioned heparin in the treatment of venous thromboembolism. Arch Intern Med 2000;160:181-188.
19. Yusen RD, Haraden BM, Gage BF, et al. Criteria for outpatient management of proximal lower extremity deep venous thrombosis Chest 1999;115:972-979.
20. O'Brien B, Levine M, Wilan A, et al. Economic evaluation of outpatient treat ment with low molecular weight heparin for proximal vein thrombosis. Arch Intern Med 1999;2298-2304.
21. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114(Suppl):445S-69S.
22. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907.
23. Schulman S, Granqvist S, Holmstrom M, et al. The duration of anticoagulant therapy after a second episode of venous thromboembolism. N Eng J Med 1997;336:393-398.
24. Van den Belt AGM, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with a familial thrombophilia. Arch Intern Med 1997; 157:2227-2232.
25. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995;2:227-229.
26. Goldhaber SZ, Haire WD, Heidstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right ventricular function and pulmonary perfusion. Lancet 1993;341-507-511.
27. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolyric treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997; 96:882-888.
28. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-1171.
29. Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80:184-188.
30. Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med 1988;318:1512-1520; 1585-1594.
31. Urokinase Pulmonary Embolism Trial. Phase I results. JAMA 1970;214:2163-2172.
32. Urokinase Streptokinase Pulmonary Embolism Trial. Phase II Results. JAMA 1974;229:1606-1613.
33. Goldhaber SZ, Kessler CM, Heit J, et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293-298.
34. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one year follow-up. J Am Coll Cardiol 1998;31:1057-1063.
35. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest 1999;6:1695-1707.
36. Goldhaber SZ. Thrombolytic therapy in venous thromboembolism: clinical trials and current indications. Clin Chest Med 1995;16:307-320.
37. Levine MN. Thrombolytic therapy for venous thromboembolism: complications and contraindications. Chin Chest Med 1995;16:321-328.
38. Goldhaber SZ. Thrombolytic therapy. Adv Intern Med 1999;44:311-325.
39. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double-bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999;138:39-44.
40. Goldhaber SZ. Pulmonary embolism thrombolysis: do we need another agent? Am Heart J 1999;138:1-2.
41. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998;114(Suppl):561S-578S.
42. Schmitz-Rode T, Janssens U, Schild HH, et al. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest 1998; 114: 1427-1436.
43. Koning R, Cribier A, Gerber L, et al. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. Circulation 1997;96:2498-2500.
44. Fedullo PF, Auger WR, Channick RN, et al. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 1995;16:353-374.
45. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters: indications, safety, effectiveness. Arch Int Med 1992;152:1985-1994.
46. Haire WD. Vena cava filters for the prevention of pulmonary embolism. N Engl J Med 1998;338:463-464.
47. Decousus H, Leizorovicz A, Parent F, et al. A clerical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med 1998;338:409-415.
48. Gosin JS, Graham AM, Ciocca RG, et al. Efficacy of prophylactic vena cava filters in high-risk trauma patients. Ann Vasc Surg 1997;11:100-105.
49. McMurtry AL, Owings JT, Anderson JT, et al. Increased use of prophylactic vena cava filters in trauma patients failed to decrease overall incidence of pulmonary embolism. J Am Coll Surg 1999;189:314-320.
50. Linsenmaier U, Rieger J, Schenk F, et al. Indications, management, and complications of temporary inferior vena cava filters. Cardiovasc Intervent Radiol 1998;21:464-469.
51. Ramos R, Salem KI, DePawlikowski MP, et al. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996;109:82-85.
52. Clagett GP, Anderson FA, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998;114(Suppl):531S-60S.
53. Etchells E, McLeod RS, Geerts W, et al. Economic analysis of low dose heparin vs the low molecular weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intent Med 1999;159:1221-1228.
54. Hirsh J. Evidence for the needs of out of hospital thrombosis prophylaxis. Chest 1998;114(Suppl):113S-4S.
55. Frishman WH. Recent advances in cardiovascular pharmacology. Curr Probl Cardiol 2000;25:221-296.
56. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
57. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 2000;1995:160: 334-340.